Novartis Ag

University of Pennsylvania

Morphosys Ag

Scil Proteins Gmbh

Hilmar Erhard Ebersbach

Qilong Wu

Reshma Singh

Celeste Richardson

Michael C Milone

Jennifer Brogdon

David Jonathan Glass

Thomas Huber

Joan Mannick

Leon Murphy

Jiquan Zhang

Julia Jascur

Carl H June

Yongqiang Wang

Huijuan Song

Marco Ruella

Gabriela Plesa

Eugene Choi

Heather Huet

Josef Prassler

Thomas Pietzonka

Yvonne Stark

Lai Wei

Qiumei Yang

Stefanie Thiel

David Ott

Ute Keck

Saar Gill

Erik Fiedler

Avery D Posey

Ulrike Fiedler

Saad Kenderian

Boerje Haraldsson

Thomas Hey

Guido Junge

Jihyun Lee

Agostino Cirillo

Max Warncke

Regina Link

Chao Zou

Michael Daley

The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.

Treatment of cancer using a CD33 chimeric antigen receptor

Provided herein are solubilized apyrase polypeptides, nucleotides encoding such solubilized apyrase polypeptides, pharmaceutical compositions containing such solubilized apyrase polypeptides, therapeutic uses of such solubilized apyrase polypeptides. Also provided herein are methods useful for preventing or treating tissue damage, e.g., by administering a solubilized apyrase polypeptide or pharmaceutical composition thereof, and methods for producing such solubilized apyrase polypeptides.

Solubilized apyrases, methods and use

The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

Anti-BCMA chimeric antigen receptor

The present invention provides synthetic rodent antibody libraries, such as mouse or rat antibody libraries, as well as polypeptides, nucleic acids, vectors, host cells and methods used in conjunction with these libraries. The present invention also provides antibodies isolated from such libraries and variants of such antibodies.

Rodent combinatorial antibody libraries

The invention provides compositions and methods for treating diseases associated with expression of CLL-1. The invention also relates to chimeric antigen receptor (CAR) specific to CLL-1, vectors encoding the same, and recombinant cells comprising the CLL-1 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CLL-1 binding domain.

Treatment of cancer using a CLL-1 chimeric antigen receptor

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

The present invention relates to conjugates containing a covalent linkage between one or more polypeptide molecules based on gamma-crystallin or ubiquitin and one or more functional components. Furthermore, the present invention relates to a method for the preparation of such a conjugate as well as to the use of the conjugate in diagnostics, therapy and chromatography.

Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography

Growing community of inventors

Basel, Switzerland

Hilmar Erhard Ebersbach